
Key points:
More than 80% of infants shed live polio virus after vaccination
The study, conducted by the Institute of Medical Biology in China, followed 1,200 infants who received either a bivalent (types 1 and 3) or trivalent (types 1, 2, and 3) OPV. The results are staggering: more than 80% of infants tested positive for poliovirus in their stool just seven days after vaccination. Moreover, over 10% of these infants continued to shed virus for up to 28 days.
Worse still, these vaccine-derived viruses don't simply disappear; they evolve, regaining their strength and pathogenicity. The study confirms what polio researchers have long known: OPV-derived viruses can cause polio, with no meaningful difference between wild and vaccine-derived polio viruses.
Vaccine-derived polioviruses now cause 828% more paralysis than wild polio
The implications are alarming. Despite the eradication of wild poliovirus types 2 (WPV2) and 3 (WPV3), vaccine-derived polio viruses (VDPVs) are now the primary cause of polio outbreaks worldwide. Between 2018 and 2023, there were only 397 wild poliovirus cases globally, but 3,684 cases caused by circulating vaccine-derived strains (cVDPV). That means vaccine-derived polio caused approximately 828% more cases than wild polio.
"The majority of global paralytic poliomyelitis cases are now attributed to poliovirus shedding from OPV rather than WPV," the study states.
Type 3 shedding poses the greatest threat
Among the three polio types, type 3 had the longest shedding duration, the highest shedding rate, and the fastest mutation accumulation. Multiple mutation hotspots were identified, with some shifting the virus back to neurovirulent forms, capable of paralyzing vaccine recipients and their close contacts.
OPV replicates in the gut and can be excreted via stool and other bodily fluids. The study confirms that vaccinated children can transmit the virus to their close contacts, including unvaccinated children, allowing it to circulate and mutate rapidly in the community.
WHO's failed pivot: From tOPV to bOPV
In 2016, the World Health Organization (WHO) attempted to mitigate risk by removing type 2 from the trivalent OPV (tOPV), replacing it with bivalent OPV (bOPV, types 1 and 3). However, this move backfired, with the study noting a slight increase in the shedding rate of type 3 following the removal of type 2. Without type 2 to balance replication competition in the gut, type 3 replicated and mutated more aggressively, leading to rising cVDPV3 detection rates in recent years.
IPV alone doesn't stop transmission. Although inactivated polio vaccine (IPV) is safer and doesn't replicate in the gut, it also doesn't halt fecal-oral spread. This leaves a dangerous gap, allowing silent transmission even as the world moves toward polio eradication.
This new evidence confirms what global health authorities have tried to obscure: OPV is not just risky; it is driving outbreaks. To eradication efforts, OPV recipients shed virus that mutates rapidly, spreads to others, and causes polio in areas of low vaccination coverage. In 2025, the dominant strains of polio circulating in the world will no longer come from nature; they will come from the vaccine itself.
Sources include:
Nature.com
JonFleetwood.substack.com
Pubmed.gov
Source link